Uwell Biopharma, Inc. (TPEX:7902)

Uwell Biopharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	85.27	60.24	43.4	23.09	27.71	49.76
Short-Term Investments	200	260	4.5	63	-	18
Cash & Short-Term Investments	285.27	320.24	47.9	86.09	27.71	67.76
Cash Growth	29.49%	568.62%	-44.37%	210.70%	-59.11%	89.86%
Other Receivables	0.62	0.46	0.04	0.07	0	0.02
Receivables	0.62	0.46	0.04	0.07	0	0.02
Prepaid Expenses	2.19	0.46	0.46	0.71	0.48	4.32
Other Current Assets	0.01	0.1	0.09	0.05	0.27	0.06
Total Current Assets	288.08	321.26	48.48	86.91	28.46	72.16
Property, Plant & Equipment	32.67	19.53	19.56	25.48	26.6	33.11
Other Intangible Assets	1.36	0	0.04	0.09	0.23	0.43
Other Long-Term Assets	9.59	8.34	8.08	6.04	5.11	0.58
Total Assets	331.7	349.13	76.16	118.51	60.4	106.27

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	8.8	9.02	5.36	4.42	5.62	5.52
Current Portion of Leases	5.21	2.56	4.25	4.14	3.4	4.19
Other Current Liabilities	6.2	1.47	1.09	0.49	0.8	1.09
Total Current Liabilities	20.21	13.05	10.7	9.05	9.81	10.8
Long-Term Leases	6.69	1.69	0.86	3.98	4.95	8.34
Total Liabilities	26.89	14.75	11.56	13.03	14.76	19.15

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	200.61	200	117	117	57	251.8
Additional Paid-In Capital	144.16	255.48	2.54	47.54	2.54	3.18
Retained Earnings	-40.42	-121.5	-55.3	-59.43	-14.26	-168.23
Comprehensive Income & Other	0.46	0.4	0.38	0.38	0.37	0.37
Shareholders' Equity	304.8	334.38	64.61	105.48	45.64	87.13
Total Liabilities & Equity	331.7	349.13	76.16	118.51	60.4	106.27

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	11.89	4.26	5.11	8.12	8.34	12.53
Net Cash (Debt)	273.37	315.98	42.79	77.98	19.37	55.23
Net Cash Growth	25.55%	638.50%	-45.13%	302.67%	-64.94%	188.23%
Net Cash Per Share	1.40	2.06	0.37	0.88	0.34	2.34
Filing Date Shares Outstanding	200.61	200	117	117	57	29.2
Total Common Shares Outstanding	200.61	200	117	117	57	29.2
Working Capital	267.87	308.21	37.79	77.86	18.65	61.36
Book Value Per Share	1.52	1.67	0.55	0.90	0.80	2.98
Tangible Book Value	303.44	334.38	64.57	105.4	45.41	86.7
Tangible Book Value Per Share	1.51	1.67	0.55	0.90	0.80	2.97
Machinery	25.66	18.47	16.44	16.44	14.44	14.31
Construction In Progress	-	-	-	-	-	5.79
Leasehold Improvements	10.82	10.82	9.32	9.32	9.32	3.19

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 5, 2026

Data Sources Report a data error